Home 禄 Metro 禄 Health and Science
Spit's official - lizards to the rescue in type 2 diabetes war
By Cai Wenjun |
00:59 UTC+8 September 1, 2009
|
Print Edition
Print Edition
A DRUG containing lizard saliva to help treat people with type 2 diabetes will be available in many major hospitals around the nation from late this month, a treatment forum was told in Shanghai yesterday.
About 2,000 domestic patients will receive a six-month supply of free dosage samples of the drug, with the trademark name Byetta.
All big hospitals in the city are involved in the project.
Byetta is derived from a chemical found in the saliva of the gila monster, a venomous lizard native to the southwest of the United States and northern Mexico.
The drug was marketed in the US in 2005, went on sale in Europe in 2006 and is available in about 60 countries and regions.
"It is a new medication for type 2 diabetes," Dr Yang Wenying, director of the inner-secretion department of the China-Japan Friendship Hospital in Beijing told the forum in Jin Mao Tower.
"Target patients are those who don't respond well to oral medicine but who don't require insulin treatment."
The medication works by stimulating insulin secretion in response to high levels of blood sugar. It also inhibits glucagon, a hormone that increases blood sugar.
Type 2 diabetes, often called non-insulin-dependent diabetes, is the more common form of the disease.
Type 1 diabetes patients must inject insulin because their bodies can't produce it.
People with type 2 diabetes do not produce enough insulin or their bodies don't use the insulin adequately.
Type 2 diabetes is usually associated with an unhealthy lifestyle.
According to the Ministry of Health, there are about 20 million of diabetes patients on Chinese mainland and this number will grow to 60 million in 2025.
About 93 percent of diabetes in the nation is type 2.
Byetta is taken by injection through a pen-injection device, according to the maker, Eli Lilly and Co.
About 2,000 domestic patients will receive a six-month supply of free dosage samples of the drug, with the trademark name Byetta.
All big hospitals in the city are involved in the project.
Byetta is derived from a chemical found in the saliva of the gila monster, a venomous lizard native to the southwest of the United States and northern Mexico.
The drug was marketed in the US in 2005, went on sale in Europe in 2006 and is available in about 60 countries and regions.
"It is a new medication for type 2 diabetes," Dr Yang Wenying, director of the inner-secretion department of the China-Japan Friendship Hospital in Beijing told the forum in Jin Mao Tower.
"Target patients are those who don't respond well to oral medicine but who don't require insulin treatment."
The medication works by stimulating insulin secretion in response to high levels of blood sugar. It also inhibits glucagon, a hormone that increases blood sugar.
Type 2 diabetes, often called non-insulin-dependent diabetes, is the more common form of the disease.
Type 1 diabetes patients must inject insulin because their bodies can't produce it.
People with type 2 diabetes do not produce enough insulin or their bodies don't use the insulin adequately.
Type 2 diabetes is usually associated with an unhealthy lifestyle.
According to the Ministry of Health, there are about 20 million of diabetes patients on Chinese mainland and this number will grow to 60 million in 2025.
About 93 percent of diabetes in the nation is type 2.
Byetta is taken by injection through a pen-injection device, according to the maker, Eli Lilly and Co.
- About Us
- |
- Terms of Use
- |
-
RSS - |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔＄粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.
